Royalty Net Income Per Share from 2010 to 2025

RPRX Stock  USD 33.42  0.09  0.27%   
Royalty Pharma Net Income Per Share yearly trend continues to be fairly stable with very little volatility. Net Income Per Share is likely to outpace its year average in 2025. During the period from 2010 to 2025, Royalty Pharma Net Income Per Share regression line of annual values had r-squared of  0.08 and arithmetic mean of  1.87. View All Fundamentals
 
Net Income Per Share  
First Reported
2010-12-31
Previous Quarter
1.91900417
Current Value
2.49
Quarterly Volatility
1.58784991
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 237.3 M, Total Revenue of 2.4 B or Research Development of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.79, Dividend Yield of 0.0362 or PTB Ratio of 1.05. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Royalty Pharma Plc over the last few years. It is Royalty Pharma's Net Income Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
6.421.321.150.102.541.922.49-79%-13%-91%2497%-24%30%100%
       Timeline  

Royalty Net Income Per Share Regression Statistics

Arithmetic Mean1.87
Geometric Mean1.34
Coefficient Of Variation84.91
Mean Deviation1.18
Median1.15
Standard Deviation1.59
Sample Variance2.52
Range6.3207
R-Value0.29
Mean Square Error2.48
R-Squared0.08
Significance0.28
Slope0.1
Total Sum of Squares37.82

Royalty Net Income Per Share History

2025 2.49
2024 1.92
2023 2.54
2022 0.0978
2021 1.15
2020 1.32
2019 6.42

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Net Income Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per Share 1.92  2.49 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.